X-linked Hypophosphatemia Clinical Trials

41 clinical trials for X-linked Hypophosphatemia across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phosphorus-31 Spectroscopy in Phosphate Diabetes — RECRUITING · NA
• Registry for Patients With X-Linked Hypophosphatemia — RECRUITING
• Effective Dosing of Burosumab in XLH — RECRUITING
• A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia — RECRUITING · PHASE1
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF KRN23 VERSUS ORAL PHOSPHATE AND ACTIVE VITAMIN D TREATMENT IN PEDIATRIC PATIENTS WITH X LINKED HYPOPHOSPHATEMIA (XLH) — RECRUITING · PHASE3
• A Multicenter, Open-label, Phase 1/2, Dose-escalation and Subsequent Safety Extension Study of Subcutaneous KK8123 in Adult Patients with X-linked Hypophosphatemia — TERMINATED · PHASE1
• A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth — COMPLETED
• Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia — NOT_YET_RECRUITING
• X-linked Hypophosphatemia Disease Monitoring Program — ACTIVE_NOT_RECRUITING
• Calcitriol Monotherapy for X-Linked Hypophosphatemia — COMPLETED · PHASE1
• Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners — ACTIVE_NOT_RECRUITING
• Baby Detect : Genomic Newborn Screening — COMPLETED
• Burden of Disease and Functional Impairment in XLH — ACTIVE_NOT_RECRUITING
• A MULTICENTER, OPEN-LABEL, PHASE 1/2, DOSE ESCALATION AND SUBSEQUENT SAFETY EXTENSION STUDY OF SUBCUTANEOUS KK8123 IN ADULT PATIENTS WITH X-LINKED HYPOPHOSPHATEMIA — NOT_YET_RECRUITING · PHASE1
• Expanded Access to Burosumab — OTHER
• Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age — COMPLETED · PHASE1
• Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH — COMPLETED · PHASE3
• Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH — COMPLETED · PHASE4
• Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH — COMPLETED · PHASE4
• Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) — COMPLETED · PHASE3
• An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia — COMPLETED · PHASE1
• A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia — COMPLETED · PHASE1
• Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) — COMPLETED · PHASE3
• A Study of KRN23 in X-linked Hypophosphatemia — COMPLETED · PHASE1
• Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) — COMPLETED · PHASE2
• Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) — COMPLETED · PHASE2
• Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) — COMPLETED · PHASE2
• Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls — COMPLETED
• Retrospective and Prospective Disease Progression and Quality of Life in XLH — COMPLETED
• Foot Disorders in X-linked Hypophosphatemia — COMPLETED
• Examining the Effect of Burosumab on Muscle Function — COMPLETED · PHASE4
• Anti-FGF23 (Burosumab) in Adult Patients With XLH — COMPLETED · PHASE3
• FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP) — COMPLETED
• Dental Implants in Patients With X-linked Hypophosphatemia — OTHER
• Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH — COMPLETED · PHASE3
• Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT — OTHER · PHASE3
• X-linked Hypophosphatemia and FGF21 — COMPLETED
• Burosumab in Children and Adolescents With X-linked Hypophosphatemia — OTHER · PHASE4
• Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia — OTHER · PHASE4
• AN OPEN-LABEL, SINGLE-ARM, PHASE 3 STUDY TO EVALUATE THE EFFECTS OF KRN23 ON OTEOMALACIA IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA (XLH) — NOT_YET_RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF KRN23 IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA (XLH) — NOT_YET_RECRUITING · PHASE3

Refine this search